Becton, Dickinson and Company (NYSE:BDX) Stock Holdings Increased by Pines Wealth Management LLC

Pines Wealth Management LLC increased its holdings in Becton, Dickinson and Company (NYSE:BDX) by 20.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,425 shares of the medical instruments supplier’s stock after purchasing an additional 246 shares during the quarter. Pines Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $326,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Bank of Jackson Hole Trust bought a new stake in shares of Becton, Dickinson and Company in the 4th quarter worth approximately $25,000. REAP Financial Group LLC raised its holdings in shares of Becton, Dickinson and Company by 75.3% in the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 55 shares in the last quarter. Sierra Ocean LLC bought a new stake in shares of Becton, Dickinson and Company in the 4th quarter worth approximately $29,000. Picton Mahoney Asset Management raised its holdings in shares of Becton, Dickinson and Company by 61.4% during the fourth quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier’s stock valued at $32,000 after acquiring an additional 54 shares during the period. Finally, Nexus Investment Management ULC purchased a new stake in shares of Becton, Dickinson and Company in the 1st quarter valued at approximately $34,000. 86.97% of the stock is currently owned by institutional investors.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 479 shares of the stock in a transaction on Wednesday, April 9th. The shares were sold at an average price of $197.28, for a total transaction of $94,497.12. Following the transaction, the executive vice president now owns 4,887 shares in the company, valued at $964,107.36. This represents a 8.93% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Richard Byrd sold 1,940 shares of the stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $224.91, for a total transaction of $436,325.40. Following the transaction, the executive vice president now owns 7,411 shares in the company, valued at approximately $1,666,808.01. This trade represents a 20.75% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 4,044 shares of company stock worth $836,000 in the last 90 days. 0.36% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Barclays reduced their price target on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating for the company in a research report on Tuesday, June 3rd. Stifel Nicolaus reduced their price target on shares of Becton, Dickinson and Company from $280.00 to $224.00 and set a “buy” rating for the company in a research report on Friday, May 2nd. Bank of America downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $190.00 price target for the company. in a research report on Thursday, May 1st. Raymond James downgraded shares of Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a research report on Friday, May 2nd. Finally, Citigroup downgraded shares of Becton, Dickinson and Company from a “strong-buy” rating to a “hold” rating and reduced their price target for the company from $217.00 to $185.00 in a research report on Thursday, May 22nd. Eight investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $219.22.

Becton, Dickinson and Company Stock Up 1.4%

Becton, Dickinson and Company stock opened at $173.47 on Friday. The firm has a market cap of $49.72 billion, a PE ratio of 28.82, a P/E/G ratio of 1.63 and a beta of 0.25. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.63 and a current ratio of 1.13. The firm’s 50 day moving average price is $186.95 and its two-hundred day moving average price is $214.78. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, beating the consensus estimate of $3.28 by $0.07. The firm had revenue of $5.27 billion for the quarter, compared to analyst estimates of $5.35 billion. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. The company’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.17 EPS. On average, research analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 30th. Stockholders of record on Monday, June 9th will be paid a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, June 9th. This represents a $4.16 annualized dividend and a dividend yield of 2.40%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 79.39%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.